Business Wire

Illumination and Nintendo Announce Theatrical Release Date and Voice Cast for the Super Mario Bros. Animated Film

24.9.2021 02:46:00 EEST | Business Wire | Press release

Share

Illumination (HQ: Santa Monica, CA, USA; Founder and CEO: Chris Meledandri) and Nintendo Co., Ltd. (HQ: Kyoto, Minami-ku, Japan; Representative Director and President: Shuntaro Furukawa, “Nintendo” hereafter) today announced that their new animated film based on the world of Super Mario Bros. will be released worldwide during the 2022 holiday season. Universal Pictures will release the film in North America on December 21, 2022, with the release schedule for additional countries and regions to be announced at a future date. The film will be co-financed by Universal Pictures and Nintendo.

In addition, the two companies announced the voice actors for the characters Mario (Chris Pratt), Princess Peach (Anya Taylor-Joy), Luigi (Charlie Day), Bowser (Jack Black), Toad (Keegan-Michael Key), Donkey Kong (Seth Rogen), Cranky Kong (Fred Armisen), Kamek (Kevin Michael Richardson) and Spike (Sebastian Maniscalco). Each voice actor was cast for their ability to capture the unique spirit of their character.

This new animated film will be produced by Chris Meledandri of Illumination and Shigeru Miyamoto of Nintendo, directed by Aaron Horvath and Michael Jelenic, who previously collaborated on the animated series Teen Titans Go! and the film Teen Titans Go! To the Movies. The screenplay of the film will be written by Matthew Fogel, whose writing credits include The LEGO Movie 2: The Second Part and the upcoming Illumination film Minions: The Rise of Gru.

“Mario and Luigi are two of the most beloved heroes in all of popular culture, and we are honored to have the unique opportunity to work so closely with Shigeru Miyamoto and the widely imaginative team at Nintendo to bring these characters to life in an animated movie, unlike any film Illumination has made to date,” said Chris Meledandri, Illumination’s Founder and CEO, and outside director of Nintendo.

“We are collaborating with Chris and his experienced team to not just create a character licensed film, but a new piece of entertainment which brings Super Mario Bros. to life on the screen, and allows everyone to enjoy whether or not they know about the game. The production so far is constructive and going very well, and both parties are learning a lot from each other. We humbly ask that fans wait just a little longer for the premiere, and we hope they look forward to seeing the unique characters from Super Mario Bros. on the big screen,” said Shigeru Miyamoto, Representative Director, Fellow of Nintendo.

  • Voice cast

Mario – Chris Pratt
Princess Peach – Anya Taylor-Joy
Luigi – Charlie Day
Bowser – Jack Black
Toad – Keegan-Michael Key
Donkey Kong – Seth Rogen
Cranky Kong – Fred Armisen
Kamek – Kevin Michael Richardson
Spike – Sebastian Maniscalco
??? – Charles Martinet

  • About the Super Mario Bros. animated film

This Super Mario Bros. animated film, which will be produced by Chris Meledandri of Illumination and Shigeru Miyamoto of Nintendo, is scheduled to be released during the 2022 holiday season. It will premiere on December 21, 2022, in North America. The release schedule for additional countries and regions will be announced at a future date. The film will be co-financed by Universal Pictures and Nintendo, released worldwide by Universal Pictures.

  • About Illumination

Illumination, founded by Academy Award® nominee Chris Meledandri in 2007, is one of the entertainment industry's leading producers of event-animated films. The company's franchises include two of the top-four animated films of all time, and its iconic, beloved brands infused with memorable and distinct characters, global appeal and cultural relevance have grossed more than $6.25 billion worldwide. Illumination was honored by Fast Company as one of the world's most innovative companies.

  • About Nintendo

Nintendo Co., Ltd., headquartered in Kyoto, Japan, has created franchises that have become household names worldwide, including Mario™, Donkey Kong™, The Legend of Zelda™, Metroid™, Pokémon™, Animal Crossing™, Pikmin™ and Splatoon™, through its integrated hardware and software products. Nintendo aims to deliver unique, intuitive entertainment experiences for everyone, manufacturing and marketing video game devices such as the Nintendo Switch™ family of systems, developing and operating applications for smart devices, and collaborating with partners on a range of other entertainment initiatives like visual content and theme parks. Nintendo has sold more than 5.1 billion video games and over 800 million hardware units globally. From the launch of the Nintendo Entertainment System™ more than 30 years ago, through today and into the future, Nintendo’s continuing mission is to create unique entertainment that puts smiles on the faces of people all over the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Illumination
Sarah Levinson Rothman
sarah.rothman@ledecompany.com
917-623-6060

For Nintendo
Eddie Garcia
egarcia@golin.com
213-335-5536
or
Cindy Gordon
cindgo02@noa.nintendo.com
650-226-4040

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 10:00:00 EEST | Press release

Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao.​ Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercialization in the licensed territory under a jointly agreed China Development Plan. Merz will act as Overseas Holder of the Drug Registration Certificate and Kvvit will serve as Domestic Responsible Person, funding local clinical development and regulatory submissions.​ INBRIJA® is currently not approved in China, Hong Kong and Macao

Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 09:49:00 EEST | Press release

Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weydenthal, Rector of Poznań University of Technology Prof. Teofil Jesionowski, and industry leaders mark the occasion. The installation of the IQM Radiance R1 system at the university aligns with the strategic objectives outlined in Poland’s quantum technology development roadmap, as well as broader European initiatives in this area. Poland has a strong foundation in quantum technologies, particularly in STEM (Science, Technology, Engineering, and Mathematics) disciplines, built on high academic

BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 09:30:00 EEST | Press release

BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical scenarios. All data remains in Austria and therefore within European jurisdiction, helping organizations protect themselves from geopolitical risks, arbitrary price changes by international hyperscalers, and the risk of external shutdowns. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525934244/en/ With its own data center in Graz, the BearingPoint Fully-Owned Sovereign Infrastructure Stack enables companies and publ

Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 09:00:00 EEST | Press release

Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Phoenix from 24 to 27 May 2026. “Momentum is building across the Parkinson’s scientific community around the clinical potential of pariceract. At the GBA1 Meeting and the 7th World Parkinson Congress, we have been able to connect with this community as we appro

Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 08:00:00 EEST | Press release

Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye